Add Formweb to your mobile device
Approved Formulary
Search results for:
digoxin
digoxin
- Restricted Medications IV Push
Brand names: Lanoxin
| Form | Strength |
|---|---|
| SOLUTION, INJECTABLE | 100 mcg/mL (0.1 mg/mL) |
| TABLET, ORAL | 125 mcg (0.125 mg) |
Display Cardiotonic Agents Class:
240408
High Alert Drug
: Policy
Last updated: Sep. 18, 2025
- Hazardous Waste BLACK BUCKET
• Two RNs independently verify dose prior to administration.
(KEY: "Y" = may be given as described on chart. "N" = may NOT be given except in Rapid Response/Code Blue situations or as otherwise described in Exceptions section of Policy.
IV Push
(Brand)
(Lanoxin)
Use in heart failure: evidence for benefits and harms of digoxin is conflicting and of lower quality; most (but not all) evidence concerns use in HFrEF. There is strong evidence for other agents as firstline therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional benefits and may increase the risk of toxicity. Use caution in discontinuing digoxin among current users with HFrEF, given limited evidence suggesting worse clinical outcomes after discontinuation.
Decreased renal clearance of digoxin may lead to an increased risk of toxic effects; further dose reduction may be necessary for those with Stage 4 or 5 chronic kidney disease.
Avoid as first-line therapy for heart failure. See rationale for caution about withdrawal in long-term users with HFrEF.
If used for atrial fibrillation or heart failure, avoid dosages >0.125 mg/day.
Dosage > 0.125 mg/day: moderate, Strength of Recommendation: Strong